Gradalis Inc. has announced that GRAD-1405 has demonstrated robust, dose-related tumor growth control and an impact on three key KRAS mutations.

Daewoong Pharmaceutical Co. Ltd. has divulged arginase-1 (ARG1) inhibitors reported to be useful for the treatment of cancer.

Synnovation Therapeutics Inc. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.

Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy, fibrosis, autoimmune, cardiovascular and metabolic diseases.

Onkure Inc. has received FDA clearance of its IND application for OKI-219, a mutant selective PI3Kα H1047R inhibitor, for solid tumors.

Quanta Therapeutics Inc. has announced progression of its pipeline of KRAS-directed drug candidates, with the receipt of IND approval from the FDA for QTX-3034.

Abbvie Inc. and Umoja Biopharma Inc. have announced two exclusive option and license agreements to develop multiple in situ generated chimeric antigen receptor (CAR)-T cell therapy candidates in oncology using Umoja's proprietary Vivovec platform.

Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential $540 million deal with Astrazeneca plc, Allorion inked a licensing agreement with Avenzo Therapeutics Inc. that could total more than $1 billion.

Following up on a 2021 partnership with Takeda Pharmaceutical Co. Ltd., Bridgene Biosciences Inc. has signed up a second international drug company, Galapagos NV, to use its chemoproteomic platform, IMTAC (Isobaric Mass Tagged Affinity Characterization), to discover small-molecule drug candidates.